Biocon Biologics has one of the deepest portfolios of biosimilars in the industry. Our long-term investments in R&D have yielded several molecules in diabetes, of which three have already been commercialized in across markets globally.

Glargine 100U

Approved in 100 countries, including U.S. EU countries, UK, Canada, Australia, NZ, Japan & many EM countries

Commercialized in the U.S., EU countries, Australia, Canada, India, Malaysia, Egypt, Morocco, Mexico etc

Aspart

Approved in 30+ countries, including EU countries, UK, Canada & several EM countries; Filed in U.S.

Commercialized in Canada and some EM Countries.

Recombinant Human Insulin

Approved in 45+ EM countries; Filed in U.S.

Commercialized in several emerging markets worldwide, including India, Malaysia, Mexico etc.

Glargine 300U